Gelonghui, April 8, 丨 Kanglong Chemical (03759.HK) announced that on April 8, 2024, Kangjun Investment (as general partner) signed a limited partnership agreement with eight limited partners (i.e. the company, Beijing Xinyuan Zhikang, Ningbo Yongxin, Ningbo Yongqian, Ningbo Yongcai, Zhuhai Hi-Tech, Shanghai Southern Model and Mr. Yu Yuejiang) to invest in Yongxin Kangjun Fund.
Yongxin Kangjun Fund will be registered as a limited partnership in China. Its main goal is to invest in shares, shares, equity shares of related enterprises or other economic entities with innovative technology or innovative service platforms in the biomedical field, and convertible bond investment activities for the purpose of equity investment in accordance with Chinese law. The target fundraising limit for the Yongxin Kangjun Fund is tentatively set at RMB 2 billion.
The board of directors believes that investing in Yongxin Kangjun Fund provides the company with an opportunity to promote its layout in the pharmaceutical R&D industry and other related service fields, enhance its overall competitiveness, and consolidate its position in the industry.
By participating in the investment of Yongxin Kangjun Fund, the company relies on the ability and experience of professional investment institutions investing in Yongxin Kangjun Fund partners, making full use of the ability of all parties to organize and research project information and make relevant investment decisions within the industry to expand the company's investment capacity, reduce the risk of mergers and acquisitions in the company's industry, actively seize good investment opportunities, accelerate the achievement of the company's strategic goals, and enhance the company's future profitability.